Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab in R/R Classical Hodgkin's Lymphoma
NCT03655483Phase 2Unknown
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab in classical Hodgkin lymphoma (cHL), sponsored by Guangzhou Gloria Biosciences Co., Ltd. Primary endpoint: Objective Response Rate at 2 months. Status: unknown.
02
Drugs
zimberelimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03655483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655483.